Skip to search formSkip to main contentSkip to account menu

odanacatib

Known as: (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide 
An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The subjects of optimal duration of osteoporosis treatment consequences of stopping osteoporosis 
2017
2017
Over the past decade, the osteoporosis landscape has changed. Even though more treatment options are available, fewer… 
2017
2017
Cathepsin K (CatK) is the predominant mammalian bone-degrading protease and thus an ideal target for antiosteoporotic drug… 
2013
2013
SummaryThe efficacy and safety of oral placebo or odanacatib 10, 25, or 50 mg once weekly for 52 weeks were evaluated in a double… 
Review
2010
Review
2010
OBJECTIVE To describe recently discovered agents for the management of osteoporosis. METHODS A literature review (PubMed search… 
2009
2009
Abstract Odanacatib (MK-0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under…